Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.79 |
| ▸ | PKM | P14618 | 2/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.79 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.79 |
| ▸ | RELA | Q04206 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | MMP8 | P22894 | 1/20 | 0.64 |
| ▸ | MMP13 | P45452 | 1/20 | 0.64 |
| ▸ | SCD | O00767 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877470 | 0.89 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL28308136 | 0.85 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL7452479 | 0.82 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL24751 | 0.81 | HSD17B1 (0.62) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| Bromide SCHEMBL28862925 | 0.79 | HSD17B1 (0.61) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL1987139 | 0.78 | MMP2 (1.00) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL17916702 | 0.78 | SCD (1.00) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL16562181 | 0.78 | SCD (0.73) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL14340278 | 0.76 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL14516684 | 0.76 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PKMNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | NPC1 840/4885RAB9A 4781/4885SMN1; SMN2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.